Entity
Description
  • Value proposition

    French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities

    AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis.

    Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

  • AdipoPharma, the adipocyte curing company

    By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes

  • https://www.adipopharma.com/
Corporate interactions BETA
Corporate TypeTweets Articles
BASF
BASF
Chemistry, Chemical Manufacturing
BASF
Chemistry, Chemical Manufacturing
Other

6 Oct 2023


Veolia
Veolia
Energy, Environmental Services
Veolia
Energy, Environmental Services
Other

6 Oct 2023


France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

8 Jul 2023


SATT CONECTUS
SATT CONECTUS
Research, Research Services
SATT CONECTUS
Research, Research Services
Other

23 Jan 2023


Similar entities
Loading...
Loading...
Social network dynamics